IDEAYA Biosciences clinical trials we track

Check company identity source

Phase 3 1 trial

TrialDrugs studiedStatusPrimary completion
Neoadjuvant Darovasertib in Primary Uveal MelanomaNCT07015190Darovasertib, Primary Local TherapyRecruiting2030-10Estimated

Phase 2 / 3 1 trial

TrialDrugs studiedStatusPrimary completion
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaNCT05987332Crizotinib, Dacarbazine, IDE196, Ipilimumab and 2 moreActive not recruiting2027-01-15Estimated

Phase 2 1 trial

TrialDrugs studiedStatusPrimary completion
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaNCT05907954DarovasertibActive not recruiting2027-04-30Estimated

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Progression-Free Survival (PFS) by blinded independent central review (BICR) of IDE196 + Crizotinib compared to investigator's choice of treatment Measure: Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment. After: Measure: Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following: Measure: Phase 2 Progression-Free Survival (PFS) Measure: Phase 3 Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment..

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source